1.Tobacco Use in Bipolar Disorder.
Daniel THOMSON ; Michael BERK ; Seetal DODD ; Marta RAPADO-CASTRO ; Shae E QUIRK ; Pernille K ELLEGAARD ; Lesley BERK ; Olivia M DEAN
Clinical Psychopharmacology and Neuroscience 2015;13(1):1-11
Tobacco use in mental health in general and bipolar disorder in particular remains disproportionally common, despite declining smoking rates in the community. Furthermore, interactions between tobacco use and mental health have been shown, indicating the outcomes for those with mental health disorders are impacted by tobacco use. Factors need to be explored and addressed to improve outcomes for those with these disorders and target specific interventions for people with psychiatric illness to cease tobacco smoking. In the context of bipolar disorder, this review explores; the effects of tobacco smoking on symptoms, quality of life, suicidal behaviour, the biological interactions between tobacco use and bipolar disorder, the interactions between tobacco smoking and psychiatric medications, rates and factors surrounding tobacco smoking cessation in bipolar disorder and suggests potential directions for research and clinical translation. The importance of this review is to bring together the current understanding of tobacco use in bipolar disorder to highlight the need for specific intervention.
Bipolar Disorder*
;
Mental Health
;
Psychotropic Drugs
;
Quality of Life
;
Smoke
;
Smoking
;
Smoking Cessation
;
Tobacco Use*
2.Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder.
Sung Wan KIM ; Seetal DODD ; Lesley BERK ; Jayashri KULKARNI ; Anthony DE CASTELLA ; Paul B FITZGERALD ; Jae Min KIM ; Jin Sang YOON ; Michael BERK
Psychiatry Investigation 2015;12(3):349-355
OBJECTIVE: To investigate the impact of regular cannabis use on long-term remission of mood symptoms in bipolar spectrum disorders. METHODS: The 24-month prospective observational study included patients (n=239) with bipolar I disorder and schizoaffective disorder, bipolar type. Participants were classified as regular cannabis users (three times or more per week) or non-users. The primary outcome measure was the achievement of remission on the evaluations during the 24 months. RESULTS: Of the 234 participants for whom data was available, 25 (10.7%) were regular cannabis users, and the group comprised significantly more males than females. In the total population, cannabis use was significantly associated with decreased likelihood of remission during the 24-month follow-up period. Subgroup analyses showed that cannabis use was significantly associated with lower remission rates on the Hamilton Depression Rating Scale in females (n=139) and patients prescribed mood stabilizers alone (n=151), whereas in males (n=95) and patients prescribed olanzapine and/or a mood stabilizer (n=83), cannabis use was significantly associated with lower remission rates on the Young Mania Rating Scale. Remission rates were lowest in the concurrent cannabis and tobacco smoking group (n=22) followed by the tobacco smoking only group (n=97), and the non-smoker group (n=116). The post-hoc analysis revealed that all remission rates were significantly lower in the concurrent cannabis and the tobacco smoking group compared to the non-smoker group. CONCLUSION: Cannabis use negatively affects the long-term clinical outcome in patients with bipolar spectrum disorders. A comprehensive assessment and integrated management of cannabis use are required to achieve better treatment outcomes for bipolar spectrum disorders.
Bipolar Disorder
;
Cannabis*
;
Depression
;
Female
;
Follow-Up Studies
;
Humans
;
Male
;
Observational Study
;
Outcome Assessment (Health Care)
;
Prospective Studies
;
Psychotic Disorders*
;
Smoking
3.Effects of Persisting Emotional Impact from Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: A Pilot Study.
Ajeet Bhagat SINGH ; Chad A BOUSMAN ; Chee Hong NG ; Keith BYRON ; Michael BERK
Clinical Psychopharmacology and Neuroscience 2015;13(1):53-61
OBJECTIVE: Previous studies suggest child abuse and serotonergic polymorphism influence depression susceptibility and anti-depressant efficacy. Polymorphisms of the norepinephrine transporter (NET) may also be involved. Research in the area is possibly clouded by under reporting of abuse in researcher trials. METHODS: Adults (n=51) with major depressive disorder has 8 weeks treatment with escitalopram or venlafaxine. Abuse history was obtained, the ongoing emotional impact of which was measured with the 15-item impact of event scale (IES-15). The 17-item Hamilton Depression Rating Scale (HDRS) was applied serially. Two NET polymorphisms (rs2242446 and rs5569) were assayed, blinded to HDRS ratings and abuse history. RESULTS: No subjects reporting abuse with high impact in adulthood (IES-15 > or =26, n=12) remitted; whereas 77% reporting low impact (IES-15 <26; n=26) remitted (p<0.001). Subjects reporting high impact abuse (n=12) had a 50-fold (95% confidence interval=4.85-514.6) greater odds of carrying rs2242446-TT genotype, but the small sample size leaves this finding vulnerable to type I error. CONCLUSION: The level of persisting impact of child abuse appears relevant to antidepressant efficacy, with susceptibility to such possibly being influence by NET rs2242446 polymorphism. Larger studies may be merited to expand on this pilot level finding given potential for biomarker utility.
Adult
;
Antidepressive Agents
;
Child
;
Child Abuse*
;
Citalopram
;
Depression*
;
Depressive Disorder, Major
;
Genetic Variation*
;
Genotype
;
Humans
;
Norepinephrine Plasma Membrane Transport Proteins*
;
Pilot Projects*
;
Sample Size
;
Venlafaxine Hydrochloride
4.N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review.
Georgina OLIVER ; Olivia DEAN ; David CAMFIELD ; Scott BLAIR-WEST ; Chee NG ; Michael BERK ; Jerome SARRIS
Clinical Psychopharmacology and Neuroscience 2015;13(1):12-24
OBJECTIVE: Obsessive compulsive and related disorders are a collection of debilitating psychiatric disorders in which the role of glutamate dysfunction in the underpinning neurobiology is becoming well established. N-acetyl cysteine (NAC) is a glutamate modulator with promising therapeutic effect. This paper presents a systematic review of clinical trials and case reports exploring the use of NAC for these disorders. A further objective was to detail the methodology of current clinical trials being conducted in the area. METHODS: PubMed, Web of Science and Cochrane Library Database were searched for human clinical trials or case reports investigating NAC in the treatment of obsessive compulsive disorder (OCD) or obsessive compulsive related disorders. Researchers with known involvement in NAC studies were contacted for any unpublished data. RESULTS: Four clinical trials and five case reports/series were identified. Study durations were commonly 12-weeks, using 2,400-3,000 mg/day of NAC. Overall, NAC demonstrates activity in reducing the severity of symptoms, with a good tolerability profile and minimal adverse effects. Currently there are three ongoing randomized controlled trials using NAC for OCD (two adults and one pediatric), and one for excoriation. CONCLUSION: Encouraging results have been demonstrated from the few pilot studies that have been conducted. These results are detailed, in addition to a discussion of future potential research.
Adult
;
Cysteine*
;
Glutamic Acid
;
Humans
;
Neurobiology
;
Obsessive-Compulsive Disorder
5.Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress.
Stephen J WOOD ; Murat YÜCEL ; Christos PANTELIS ; Michael BERK
Annals of the Academy of Medicine, Singapore 2009;38(5):396-396
Mitochondrial dysfunction and oxidative stress are increasingly implicated in the pathophysiology of schizophrenia. The brain is the body's highest energy consumer, and the glutathione system is the brain's dominant free radical scavenger. In the current paper, we review the evidence of central and peripheral nervous system anomalies in the oxidative defences of individuals with schizophrenia, principally involving the glutathione system. This is reflected by evidence of the manifold consequences of oxidative stress that include lipid peroxidation, protein carboxylation, DNA damage and apoptosis - all potentially part of the process of neuroprogression in the disorder. Importantly, oxidative stress is amenable to intervention. We consider the clinical potential of some possible interventions that help reduce oxidative stress, via augmentation of the glutathione system, particularly N-acetyl cysteine. We argue that a better understanding of the mechanisms and pathways underlying oxidative stress will assist in developing the therapeutic potential of this area.
Acetylcysteine
;
Glutathione
;
Humans
;
Magnetic Resonance Imaging
;
Mitochondrial Diseases
;
Nervous System
;
physiopathology
;
Oxidative Stress
;
Schizophrenia
;
physiopathology
6.Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial.
Olivia May DEAN ; Michael MAES ; Melanie ASHTON ; Lesley BERK ; Buranee KANCHANATAWAN ; Atapol SUGHONDHABIROM ; Sookjareon TANGWONGCHAI ; Chee NG ; Nathan DOWLING ; Gin S MALHI ; Michael BERK
Clinical Psychopharmacology and Neuroscience 2014;12(3):180-188
While current pharmacotherapies are efficacious, there remain a clear shortfall between symptom remission and functional recovery. With the explosion in our understanding of the biology of these disorders, the time is ripe for the investigation of novel therapies. Recently depression is conceptualized as an immune-inflammatory and nitro-oxidative stress related disorder. Minocycline is a tetracycline antibiotic that has anti-inflammatory, pro-oxidant, glutamatergic, neurotrophic and neuroprotective properties that make it a viable target to explore as a new therapy. This double blind, randomised, placebo controlled adjunctive trial will investigate the benefits of 200 mg/day of minocycline treatment, in addition to any usual treatment, as an adjunctive treatment for moderate-severe major depressive disorder. Sixty adults are being randomised to 12 weeks of treatment (with a 4 week follow-up post-discontinuation). The primary outcome measure for the study is mean change on the Montgomery-Asberg Depression Rating Scale (MADRS), with secondary outcomes including the Social and Occupational Functioning Assessment Scale (SOFAS), Clinical Global Impressions (CGI), Hamilton Rating Scale for Anxiety (HAM-A), Patient Global Impression (PGI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and Range of Impaired Functioning Tool (LIFE-RIFT). Biomarker analyses will also be conducted at baseline and week 12. The study has the potential to provide new treatment targets, both by showing efficacy with a new class of 'antidepressant' but also through the analysis of biomarkers that may further inform our understanding of the pathophysiology of unipolar depression.
Adult
;
Anxiety
;
Biomarkers
;
Biology
;
Clinical Protocols
;
Depression
;
Depressive Disorder
;
Depressive Disorder, Major*
;
Drug Therapy
;
Explosions
;
Follow-Up Studies
;
Humans
;
Inflammation
;
Minocycline*
;
Outcome Assessment (Health Care)
;
Oxidative Stress
;
Quality of Life
;
Tetracycline
;
Surveys and Questionnaires
7.Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment
Gerard ANMELLA ; Alcy MEEHAN ; Melanie ASHTON ; Mohammadreza MOHEBBI ; Giovanna FICO ; Chee H. NG ; Michael MAES ; Lesley BERK ; Michele De PRISCO ; Ajeet B. SINGH ; Gin S. MALHI ; Michael BERK ; Seetal DODD ; Diego HIDALGO-MAZZEI ; Iria GRANDE ; Isabella PACCHIAROTTI ; Andrea MURRU ; Eduard VIETA ; Olivia M. DEAN
Clinical Psychopharmacology and Neuroscience 2024;22(1):33-44
Objective:
To explore illness-related factors in patients with major depressive disorder (MDD) recipients of adjunctive minocycline (200 mg/day) treatment. The analysis included participants experiencing MDD from a 12-week, double blind, placebo-controlled, randomized clinical trial (RCT).
Methods:
This is a sub-analysis of a RCT of all 71 participants who took part in the trial. The impact of illness chronicity (illness duration and number of depressive episodes), systemic illness (endocrine, cardiovascular and obesity), adverse effects and minocycline were evaluated as change from baseline to endpoint (12-week) using ANCOVA.
Results:
There was a consistent but statistically non-significant trend on all outcomes in favour of the use of adjunctive minocycline for participants without systemic illness, less illness chronicity, and fewer adverse effects.
Conclusion
Understanding the relationship between MDD and illness chronicity, comorbid systemic illness, and adverse effects, can potentially better characterise those individuals who are more likely to respond to adjunctive anti-inflammatory medications.
8.Transdiagnostic Associations between Anger Hostility and Chemokine Interferon-gamma Inducible Protein 10
Hedda SOLOEY-NILSEN ; Kristin NYGAARD-ODEH ; Magnhild Gangsoey KRISTIANSEN ; Erling Inge KVIG ; Ole Lars BREKKE ; Tom Eirik MOLLNES ; Michael BERK ; Solveig Klaebo REITAN ; Terje OIESVOLD
Clinical Psychopharmacology and Neuroscience 2024;22(2):285-294
Objective:
Many psychiatric disorders are linked to low grade systemic inflammation as measured by systemic cytokine levels. Exploration of cytokines and immune activity and their role in psychiatric symptoms may inform pathobiology and treatment opportunities. The aim of this study is to explore if there are associations between cytokines and psychiatric symptom clusters. Comparison between patients regularly using and those not using psychotropic medication is also conducted.
Methods:
This was a cross sectional naturalistic study with 132 participants from a general open inpatient psychiatric ward at the Nordland Hospital Trust, Norway. Serum levels of 28 different cytokines were assessed. Psychiatric symptoms the last week were assessed by a self-rating scale (Symptom check list, SCL-90-R) and grouped in defined clusters.Multiple linear regression model was used for statistical analyses of associations between levels of cytokines and symptoms, adjusting for possible confounding factors.
Results:
We found a positive association (p = 0.009) between the chemokine interferon-gamma inducible protein 10 (CXCL 10; IP-10) and the anger hostility cluster. No associations were found between the other symptom clusters and cytokines. IP-10 and the anger hostility cluster were positively associated (p = 0.002) in the subgroup of patients using psychotropic medication, not in the subgroup not using psychotropic medication.
Conclusion
Our analyses revealed a significant positive association between the symptom cluster anger hostility in SCL-90-R and the chemokine IP-10 in the subgroup of patients using psychotropic medications.
9.Plasma Levels of Tumor Necrosis Factor Superfamily Molecules Are Increased in Bipolar Disorder.
Izabela G BARBOSA ; Gabriela Neves VAZ ; Natalia Pessoa ROCHA ; Rodrigo MACHADO-VIEIRA ; Marcio Rogerio Diniz VENTURA ; Rodrigo B HUGUET ; Moises E BAUER ; Michael BERK ; Antônio L TEIXEIRA
Clinical Psychopharmacology and Neuroscience 2017;15(3):269-275
OBJECTIVE: Patients with bipolar disorder (BD) exhibit peripheral low-grade inflammation. The aim of the current study was to investigate the involvement of hitherto unexplored components of the tumor necrosis factor (TNF) superfamily in BD. METHODS: Eighty patients with type I BD and 50 healthy controls matched for age and gender were enrolled in this study. All subjects were assessed with the Mini-Plus to evaluate psychiatric comorbidities; the Young Mania Rating Scale and the Hamilton Depression Rating Scale to evaluate manic and depressive symptoms severity, respectively. TNF superfamily molecules (TNF, TNF-related weak inducer of apoptosis [TWEAK], TNF-related apoptosis-inducing ligand [TRAIL], soluble TNF receptor type 1 [sTNFR1], and soluble TNF receptor type 2 [sTNFR2]) levels were measured by ELISA. RESULTS: Patients with BD, regardless of mood state, presented increased plasma levels of sTNFR1 and TWEAK in comparison with controls. CONCLUSION: These findings corroborate the view that TNF superfamily may play a role in BD pathophysiology.
Apoptosis
;
Bipolar Disorder*
;
Comorbidity
;
Depression
;
Enzyme-Linked Immunosorbent Assay
;
Humans
;
Inflammation
;
Plasma*
;
Receptors, Tumor Necrosis Factor
;
TNF-Related Apoptosis-Inducing Ligand
;
Tumor Necrosis Factor-alpha*
10.Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia
Alyna TURNER ; John J MCGRATH ; Olivia M DEAN ; Seetal DODD ; Andrea BAKER ; Susan M COTTON ; James G SCOTT ; Bianca E KAVANAGH ; Melanie M ASHTON ; Adam J WALKER ; Ellie BROWN ; Michael BERK
Clinical Psychopharmacology and Neuroscience 2019;17(2):297-307
OBJECTIVE: Garcinia mangostana Linn., commonly known as mangosteen, is a tropical fruit with a thick pericarp rind containing bioactive compounds that may be beneficial as an adjunctive treatment for schizophrenia. The biological underpinnings of schizophrenia are believed to involve altered neurotransmission, inflammation, redox systems, mitochondrial dysfunction, and neurogenesis. Mangosteen pericarp contains xanthones which may target these biological pathways and improve symptoms; this is supported by preclinical evidence. Here we outline the protocol for a double-blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp (1,000 mg/day), compared to placebo, in the treatment of schizophrenia. METHODS: We aim to recruit 150 participants across two sites (Geelong and Brisbane). Participants diagnosed with schizophrenia or schizoaffective disorder will be randomized to receive 24 weeks of either adjunctive 1,000 mg/day of mangosteen pericarp or matched placebo, in addition to their usual treatment. The primary outcome measure is mean change in the Positive and Negative Symptom Scale (total score) over the 24 weeks. Secondary outcomes include positive and negative symptoms, general psychopathology, clinical global severity and improvement, depressive symptoms, life satisfaction, functioning, participants reported overall improvement, substance use, cognition, safety and biological data. A 4-week post treatment interview at week 28 will explore post-discontinuations effects. RESULTS: Ethical and governance approvals were gained and the trial commenced. CONCLUSION: A positive finding in this study has the potential to provide a new adjunctive treatment option for people with schizophrenia and schizoaffective disorder. It may also lead to a greater understanding of the pathophysiology of the disorder.
Cognition
;
Depression
;
Fruit
;
Garcinia mangostana
;
Garcinia
;
Inflammation
;
Neurogenesis
;
Outcome Assessment (Health Care)
;
Oxidation-Reduction
;
Oxidative Stress
;
Psychopathology
;
Psychotic Disorders
;
Schizophrenia
;
Synaptic Transmission
;
Xanthones